Drugs / Semaglutide
Semaglutide
Drug FDA approvedMarketed as Ozempic, Rybelsus, Wegovy
Glucagon-like peptide-1 (GLP-1) receptor agonist·First approved·2017·3 brands
- Registered trials
- 376
- Ongoing
- 127/ 34%
- Completed
- 229
- Indications
- 9
Approved indications by brand
Indications below are grouped by brand, since each brand carries its own label.
| Brand | Indication |
|---|---|
| Ozempic | Type 2 diabetes mellitus (glycemic control adjunct to diet and exercise) |
| Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CVD | |
| "Reduction of sustained eGFR decline | |
| end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease" | |
| Rybelsus | Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus |
| Reduce risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus at high cardiovascular risk | |
| Wegovy | Reduce risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight |
| Reduce excess body weight and maintain long-term weight reduction in adults/pediatric patients >=12 years with obesity and adults with overweight plus at least one weight-related comorbidity | |
| Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis in adults (accelerated approval)† |
† Added under accelerated approval. The indication may be withdrawn if confirmatory trials fail to verify clinical benefit.
Clinical trial landscape
376 registered studies reference this molecule or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 3 | 113 | 35 | 73 | |
| Phase 1 | 78 | 9 | 67 | |
| Phase 2 | 61 | 31 | 26 | |
| Unknown | 61 | 11 | 47 | |
| Phase 4 | 43 | 27 | 12 | |
| Not applicable | 16 | 11 | 3 | |
| Phase 2/3 | 3 | 2 | 1 | |
| Phase 1/2 | 1 | 1 | 0 | |
| All phases | 376 | 127 | 229 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Mechanism of action
GLP-1 receptor agonist that stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner, with minor delay in early postprandial gastric emptying.
Recent developments
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.